Summary

Herbert S. B. Baraf, M.D., is a founder of Arthritis and Rheumatism Associates, the Washington, D.C., region’s largest private practice rheumatology group. He is also the founding medical director of The Center for Rheumatology and Bone Research. He retired from private practice in 2022.

Dr. Baraf holds academic appointments as a Clinical Professor of Medicine at George Washington University in Washington, DC, and an Associate Clinical Professor at the University of Maryland in Baltimore. He earned his medical degree from the State University of New York Downstate Medical Center and completed his internship and residency at George Washington University. He completed a fellowship in rheumatology at Duke University.

He has served as principal investigator on over 300 clinical trials in rheumatology, with a particular interest in gouty arthritis. Dr. Baraf was designated as a Master of the American College of Rheumatology, and in 2014 he was awarded the ACR’s Paulding Phelps Award for service to patients and the profession. He is the 2022 awardee for the ACR’s Innovation in Clinical Care Award.

Research Statement

I have participated in clinical trials related to the therapy of gout, rheumatoid arthritis, psoriatic arthritis, degenerative joint disease, systemic lupus erythematosus, and Sjogren’s syndrome.

Scientific Publications

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.

Botson JK, Baraf HSB, Keenan RT, Albert J, Masri KR, Peterson J, Yung C, Freyne B, Amin M, Abdellatif A, Soloman N, Edwards NL, Strand V
Curr Rheumatol Rep.
2022 Jan;
24(1).
doi: 10.1007/s11926-022-01055-9
PMID: 35167037

Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.

Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J
Arthritis Rheumatol.
2020 Jan;
72(1).
doi: 10.1002/art.41063
PMID: 31353871

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase.

Keenan RT, Baraf HSB, LaMoreaux B
Rheumatol Ther.
2019 Jun;
6(2).
doi: 10.1007/s40744-019-0151-9
PMID: 30875075

Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.

Dalbeth N, Doyle AJ, McQueen FM, Sundy J, Baraf HS
Arthritis Care Res (Hoboken).
2014 Jan;
66(1).
doi: 10.1002/acr.22059
PMID: 23836458

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA
Arthritis Res Ther.
2013 Sep 26;
15(5).
doi: 10.1186/ar4318
PMID: 24286509

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP
Arthritis Res Ther.
2013 Feb 1;
15(1).
doi: 10.1186/ar4159
PMID: 23375025

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS
Ann Rheum Dis.
2013 Sep 1;
72(9).
doi: 10.1136/annrheumdis-2012-201795
PMID: 23144450

Experience

Clinical Professor of Medicine
George Washington University (1996 to present)

Founding Medical Director
Center for Rheumatology and Bone Research  (1981-2022)

Founder and Principal Physician
Arthritis and Rheumatism Associates  (1978-2022)

Last Updated: October 2022